Description
AES-350 is a potent and orally active HDAC6 inhibitor with an IC50 and a Ki of 0.0244 µM and 0.035 µM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC50 values of 0.187 µM and 0.245 µM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research[1]